Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer

Summary

This is a Phase 2, single-center, open-label, non-randomized study in patients with MIBC who cannot receive or refuse to receive cisplatin-based chemotherapy. Patients will be consecutively enrolled and treated. All patients enrolled who receive at least 1 cycle of study drug will be included in the primary and secondary endpoint analyses.

Timeline

Start

2023-09-20

Primary completion

2027-02

Completion

2027-02

Publications

• Necchi A, Maiorano BA, de Jong JJ, Proudfoot JA, Basile G, Cigliola A, Mercinelli C, Tateo V, Piacentini M, Pastorino G, Latini G, Tomasi E, Davicioni E, Moschini M, Brembilla G, Colecchia M, de Cobelli F, Briganti A, Ross JS, Pavlick DC, Montorsi F. Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study. Lancet Oncol. 2026 Apr;27(4):442-451. doi: 10.1016/S1470-2045(26)00050-1. Epub 2026 Feb 27.

Drugs

Indications